Tamoxifen induces PI3K activation in uterine cancer
Open Access
- 22 August 2025
- journal article
- research article
- Published by Springer Nature in Nature Genetics
- Vol. 57 (9) , 2192-2202
Abstract
Mutagenic processes and clonal selection contribute to the development of therapy-associated secondary neoplasms, a known complication of cancer treatment. The association between tamoxifen therapy and secondary uterine cancers is uncommon but well established; however, the genetic mechanisms underlying tamoxifen-driven tumorigenesis remain unclear. We find that oncogenic PIK3CA mutations, common in spontaneously arising estrogen-associated de novo uterine cancer, are significantly less frequent in tamoxifen-associated tumors. In vivo, tamoxifen-induced estrogen receptor stimulation activates phosphoinositide 3-kinase (PI3K) signaling in normal mouse uterine tissue, potentially eliminating the selective benefit of PI3K-activating mutations in tamoxifen-associated uterine cancer. Together, we present a unique pathway of therapy-associated carcinogenesis in which tamoxifen-induced activation of the PI3K pathway acts as a non-genetic driver event, contributing to the multistep model of uterine carcinogenesis. While this PI3K mechanism is specific to tamoxifen-associated uterine cancer, the concept of treatment-induced signaling events may have broader applicability to other routes of tumorigenesis.Keywords
Funding Information
- U.S. Department of War (W81XWH-17-1-0084)
- G.G. is partly supported by the Paul C. Zamecnik Chair in Oncology at the Massachusetts General Hospital Cancer Center.
- United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-17-1-0084)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA240243, 5K08CA191058-05)
- KWF Kankerbestrijding
This publication has 109 references indexed in Scilit:
- Adiposity and breast, endometrial, and colorectal cancer risk in postmenopausal women: Quantification of the mediating effects of leptin, C‐reactive protein, fasting insulin, and estradiolCancer Medicine, 2022
- Genome‐wide mutation analysis in precancerous lesions of endometrial carcinomaThe Journal of Pathology, 2020
- Oncogenic mutations in histologically normal endometrium: the new normal?The Journal of Pathology, 2019
- Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapyBritish Journal of Surgery, 2018
- Letter to the EditorBiometrical Journal, 2015
- Oncotator: Cancer Variant Annotation ToolHuman Mutation, 2015
- Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studiesCancer Chemotherapy and Pharmacology, 2014
- Stratified Fisher's exact test and its sample size calculationBiometrical Journal, 2013
- Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposureGenes, Chromosomes and Cancer, 2010
- Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the ratArchives of Toxicology, 2001